- Selank is a synthetic heptapeptide analogue of tuftsin studied in preclinical models for GABAergic, BDNF, and enkephalin-degradation pathways, not a compound with established human anxiolytic outcomes.
- Human data on Selank is limited and did not analyze results by sex, so any statement about how it behaves in women is extrapolation rather than measurement.
- No menstrual cycle, hormonal, perimenopause, or pregnancy and lactation data for Selank has been indexed, leaving every female-specific safety question genuinely open.
Selank is often discussed in the same breath as anxiety and calm, but the research reality is narrower and more honest than that framing suggests. It is a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin, developed as a stabilized research material for neuropeptide and behavioral studies. It has an interesting mechanistic footprint. It also has a female-evidence record that is close to blank, and the two facts belong side by side.
The pathways it engages
In vitro and in preclinical systems, Selank has been studied for its influence on GABAergic signaling, brain-derived neurotrophic factor (BDNF) expression, monoamine balance, and enkephalin-degradation pathways. Investigators designing anxiolytic and cognition-related research have used it as a research material, frequently alongside related peptides such as Semax.
The appeal for a cognitive catalog is that Selank engages a breadth of neuropeptide pathways while remaining a compact, well-characterized tool compound. That makes it useful for probing several mechanisms at once. It does not make any of those mechanisms a demonstrated human effect.
How thin the human record is
Selank's research status is early. Human data is limited, no established therapeutic dose exists in most jurisdictions, and early-study figures are reference points, not instructions. When a compound sits at this stage, the responsible move is to describe what has been studied rather than what it supposedly delivers.
Where dose figures appear in the Selank literature, they come from early studies reported for reference only. This site does not publish personal dosing, schedules, or protocols, and nothing here is medical advice.
The female-evidence gap, stated plainly
For a compound framed around anxiety, a physiology that is deeply hormone-modulated, the absence of sex-specific data is not a footnote. Here is the current state across the categories that matter.
- Menstrual cycle: no cycle-interaction data has been indexed.
- Hormonal interactions: no data on estrogen, thyroid, or contraceptive interactions.
- Perimenopause and menopause: no data in perimenopausal or menopausal populations.
- Pregnancy and lactation: no safety data exists, and absence of harm data is not evidence of safety.
- Sex differences: in the indexed literature, many studies included female subjects and none reported sex-stratified outcomes.
That last line is the recurring pattern in this field. Women were in the room, so to speak, but the analysis never separated their results out. So even where Selank has been studied in mixed populations, there is no female signal to report, only a pooled one.
The Selank compound profile carries the full evidence derivation and the standalone female-evidence fields. We track how many of the underlying studies included women precisely because the answer, right now, is what tells you the most: the mechanism is characterized, and the female-specific evidence is not.